Investigating energy pathways and drug resistance in triple negative breast cancer
Energy reprogramming-regulated oncopathways and drug resistance in triple negative breast cancer
This study is looking at how triple negative breast cancer uses energy in unique ways that make it tough to treat, and it's for patients with this type of cancer who are hoping for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10547770 on NIH RePORTER |
What this research studies
This research focuses on understanding the unique energy pathways that drive triple negative breast cancer (TNBC) and contribute to its resistance to current therapies. By utilizing advanced cell models that combine mitochondria from different cell types, researchers aim to uncover how mitochondrial energy reprogramming affects cancer progression and treatment response. The study employs various omics approaches to analyze the communication between mitochondria and the nucleus, which could lead to new therapeutic strategies for TNBC patients. The findings may help identify specific targets for more effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who have already responded well to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that improve outcomes for patients with triple negative breast cancer.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Kaipparettu, Benny Abraham — Baylor College of Medicine
- Study coordinator: Kaipparettu, Benny Abraham
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.